You searched for "patient"

1189 results found

Bupa covers accurate PSE prostate cancer blood test

A new era in prostate cancer detection is emerging with the EpiSwitch® PSE blood test, a highly accurate tool that enhances early diagnosis while significantly cutting false positives. Now covered by Bupa as a pre-biopsy test, PSE has demonstrated 94%...

Is it time for a kidney stress test?

In healthcare, what we measure shapes how we predict outcomes and intervene. For kidney health, traditional tools like estimated glomerular filtration rate (eGFR) provide only a partial picture. Relying solely on eGFR is like judging heart health with a resting...

Comparison of CHOKAI, STONE and STONE PLUS scores

The prevalence of urinary stones is steadily increasing due to changing dietary habits and living conditions, leading to a significant number of emergency department (ED) visits, primarily for severe pain. While managing pain is crucial, accurate diagnosis remains essential. Non-enhanced...

Robotic vs. open ureteral reimplantation

Ureteral stricture disease is a frequent and complex problem in urological practice, most commonly arising from iatrogenic injury. Although its exact incidence is difficult to determine, reported rates range from 0.3–2.5% following gynaecological surgery, approximately 3% after ureteroscopy, and up...

Comparing retroperitoneoscopic and endourological approaches for upper ureteric and renal pelvic calculi

Urinary tract stones affect approximately 5–10% of people in developed countries. Advances in urological treatment have provided several surgical options, including ureteroscopic lithotripsy (URSL), retrograde intrarenal surgery (RIRS), percutaneous nephrolithotomy (PCNL), extracorporeal shock wave lithotripsy (ESWL), and minimally invasive laparoscopic...

Surgical video – part 1: intraoperative video recording and storage

The use of digital technology has progressed in leaps and bounds and nowhere is this more apparent than in medicine and surgery. Footage of live surgery is now easily accessed on the internet or displayed at conferences. Thus, the 21st...

Management of RHC in prostate cancer with selective embolisation and hyperbaric oxygen therapy

Prostate cancer is one of the most prevalent malignancies affecting men worldwide. Radiotherapy is a common treatment modality for localised and locally advanced prostate cancer. While radiotherapy can be effective, it may lead to complications such as radiation-induced haemorrhagic cystitis...

Benign prostatic hyperplasia: what are the benefits and harms of various surgical management options?

Benign prostatic hyperplasia (BPH) is characterised by stromal and epithelial prostatic cell hyperplasia. The enlarged prostate may be associated with voiding and storage lower urinary tract symptoms (LUTS). These have been predominantly attributed to bladder outlet obstruction (BOO), assumed to...

Urolithiasis 4 - Staghorn calculus

Case scenario A 64-year-old woman with recurrent urinary tract infections and left flank pain undergoes investigations as an outpatient. Figure 1a. Figure 1b. 1. Describe Figures 1a and 1b. 2. Her co-morbidities are type 2 diabetes (which is well controlled)...

An amateur’s trek into the Urology Boot Camp

Driven by a strong desire to pursue a career in medicine, I was lucky to get an opportunity to attend the Urology Boot Camp at Leeds while still in sixth form. Although urology is a postgraduate specialty, I wanted to...

Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high-risk UTUC

High-risk upper tract urothelial carcinoma (UTUC) has been associated with poor survival outcomes. The authors evaluated the role of neoadjuvant chemotherapy in high-risk cases prior to radical nephroureterectomy (RNU) in terms of pathological stage of the final surgical specimen. A...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...